Clinical trials show semaglutide may help patients with type 1 diabetes
People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently approved only for type 2 diabetes, according to results from a small trial.
Semaglutide is the active ingredient in Novo Nordisk's diabetes drugs Ozempic and Rybelsus, as well as its weight-loss treatment Wegovy.